Literature DB >> 15464686

Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study).

Colleen Sam1, Joseph M Massaro, Ralph B D'Agostino, Daniel Levy, Jarvis W Lambert, Philip A Wolf, Emelia J Benjamin.   

Abstract

The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF. Anticoagulant use increased significantly in the 393 men and women (mean ages 72.5 and 79.0 years, respectively) who developed AF over the observation period: aspirin use increased from 14% to 39% in men and from 19% to 33% in women, and warfarin use increased from 10% to 39% in men and from 17% to 38% in women. There were no significant gender differences in anticoagulant use (p = 0.61), but participants using warfarin were younger. A total of 65 participants (17%) had major bleeding complications <or=5 years after initial AF. Age was not a significant predictor of bleeding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464686     DOI: 10.1016/j.amjcard.2004.06.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

Review 2.  Antithrombotic treatment in atrial fibrillation.

Authors:  L Kalra; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

3.  Revised Framingham Stroke Risk Profile to Reflect Temporal Trends.

Authors:  Carole Dufouil; Alexa Beiser; Leslie A McLure; Philip A Wolf; Christophe Tzourio; Virginia J Howard; Andrew J Westwood; Jayandra J Himali; Lisa Sullivan; Hugo J Aparicio; Margaret Kelly-Hayes; Karen Ritchie; Carlos S Kase; Aleksandra Pikula; Jose R Romero; Ralph B D'Agostino; Cécilia Samieri; Ramachandran S Vasan; Genevieve Chêne; George Howard; Sudha Seshadri
Journal:  Circulation       Date:  2017-02-03       Impact factor: 29.690

Review 4.  [New epidemiology of acute gastrointestinal hemorrhage].

Authors:  H-R Koelz; M Arn
Journal:  Chirurg       Date:  2006-02       Impact factor: 0.955

5.  Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.

Authors:  Julie C Lauffenburger; Denise H Rhoney; Joel F Farley; Anil K Gehi; Gang Fang
Journal:  Pharmacotherapy       Date:  2015-06-04       Impact factor: 4.705

6.  Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study.

Authors:  Margaret C Fang; Alan S Go; Elaine M Hylek; Yuchiao Chang; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  J Am Geriatr Soc       Date:  2006-08       Impact factor: 5.562

7.  Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs.

Authors:  Sven Pannach; Julia Goetze; Sandra Marten; Thomas Schreier; Luise Tittl; Jan Beyer-Westendorf
Journal:  J Gastroenterol       Date:  2017-02-16       Impact factor: 7.527

Review 8.  Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.

Authors:  Wendy T Chen; C Michael White; Olivia J Phung; Jeffrey Kluger; Ajibade O Ashaye; Diana M Sobieraj; Sagar Makanji; Vanita Tongbram; William L Baker; Craig I Coleman
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

9.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Authors:  Shaun G Goodman; Daniel M Wojdyla; Jonathan P Piccini; Harvey D White; John F Paolini; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Manesh R Patel; Matthew W Sherwood; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Gunter Breithardt; Keith A A Fox; Robert M Califf
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

10.  Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.

Authors:  Diana M Rydberg; Lennart Holm; Stefan Mejyr; Desirée Loikas; Karin Schenck-Gustafsson; Mia von Euler; Björn Wettermark; Rickard E Malmström
Journal:  Eur J Clin Pharmacol       Date:  2013-10-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.